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Abstract 
Breast cancer is one of the common cancers in the worldwide. Most of breast cancer are sporadic. BRCA1 
expression levels are reduced or totally loss in sporadic breast cancer. BRCA1 promoter methylation as one of 
the mechanisms to inactivating its function. BRCA1 promoter methylation associated with triple negative breast 
cancer (TNBC), poor prognosis, high grade, negativity of estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2(HER2). This study aims are to examine prevalence and 
correlation between BRCA1 promoter methylation and clinicopathology appearance in Indonesian women 
breast cancer. Subject are women with primary breast cancer and their formalin-fixed paraffin -embedded 
(FFPE) tumor specimen retrieved.  
------------------------------------------------------------------------ 
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DNA was isolated and subjected to methylation specific PCR(MSPCR). DNA was isolated from primary tumor 
of 113 samples. Median age at diagnosis was 48 years (with range 28-80 years). Most of them, 67(59,3%) are 
include in aged categories <50 years. Incidence BRCA promoter methylation was found 82,3% (93 of 113.) 
There is significant correlation with BRCA1 promoter methylation with age<50 years old (p-value = 0.038) and 
Luminal B subtype (p-value = 0.033). Conclusion: BRCA1 promoter methylation in Indonesian women higher 
than other nations, correlate with younger patient and Luminal B subtype. 
Keywords: Breast cancer; BRCA1 promoter methylation; prognosis. 
1. Introduction  
Breast cancer is one of the common cancers in the worldwide. Globocan 2012 reported 1.67 million new cases 
of breast cancer are found [1]. Breast cancer is the most common cancer in Indonesia with incidence 18.6 
patient per 100,000 people [2].  Germline mutations in BRCA1 approximately 5-10% in breast cancer, and the 
others were sporadic breast cancer [3,4].  BRCA1 expression levels are reduced or totally loss in sporadic breast 
cancer. Some mechanism could decreased BRCA expression, one of them is hypermethylation of BRCA1 
promoter [4, 5].  Normally BRCA1 promoter is hypomethylation, but aberrant addition of methyl groups in CpG 
island inhibit transcription factor  that regulate the BRCA1 promoter to production of this tumor suppressor 
protein, and thus their loss or gain of function [4]. Many research’s had done to prove role of BRCA1 
methylation in development sporadic breast cancer, as predictor prognosis and therapy [6–9]. BRCA1 promoter 
methylation is observed in 13-59,2% of sporadic breast cancer [6, 7,10–15]. Generally BRCA1 promoter 
methylation associated with triple negative breast cancer (TNBC), poor prognosis, high grade, negativity of 
estrogen receptor(ER), progesterone receptor (PR) and human epidermal growth factor receptor 2(HER2)[9, 11, 
12]. This study aims are to examine prevalence and correlation between BRCA1 promoter methylation and 
clinicopathology appearance in Indonesian women breast cancer. 
2. Materials and Method  
2.1 Collection of samples 
This is an analytical study using retrospective cohort to assess the correlation between clinicopathological 
appearance and BRCA1 promoter methylation on women who suffered primary breast cancer. This research was 
conducted in HUMRC (Hassanuddin University Medical Research Center) laboratory, Makassar, South 
Sulawesi.  
The study subject was all women suffered from primary breast cancer who underwent operation in MRCCC 
Siloam Hospital Semanggi, Jakarta during 2011-2015 and never got neoadjuvant chemotherapy before surgery. 
Inclusion criteria were the patient who have good formalin-fixed paraffin -embedded (FFPE) block, had been 
examined ER, PR, HER 2 and Ki67 immunohistochemistry staining, and have good medical record. Follow up 
had done until March 27th2018. Exclusion criteria was patient who have bilateral breast cancer. We performed 
clinicopathological data collection which involved age, histology type, grading, staging, ER, PR, HER2, Ki67 
and metastatic. For ER and PR, if we found nuclei staining >1% are positive  and < 1% are negative [16]. HER2 
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positive , if > 10% tumor cells showed score +3 (membrane staining strong and complete) and negative if score 
0, +1 and +2 but no showed amplification in fluorescent insitu hybridization(FISH)[17].  Ki-67 is negative if 
there is <14% of nuclei staining and positive if >14%. Based on immunohistochemistry staining we categorized 
molecular subtype according St Gallen consensus [18]. 
2.2 BRCA1 promoter methylation 
Tumor-dense areas of FFPE tissue sections were manually dissected for 4 sections, each with a thickness 10 µm 
and genomic DNA (gDNA) was isolated by QIAamp® DNA FFPE Tissue Kit (Qiagen), and bisulfite converted 
using the EpiTect® Bisulfite Kit (Qiagen). Purified converted DNA was subjected to methylation-specific PCR 
(MSPCR) using the EpiTect® MSP Kit (Qiagen). The unmethylated template primers were (forward) 
TTGGTTTTTGTGGTAATGGAAAAGTGT and (reverse) CAAAAAATCTCAACAAACTCACACCA, 
resulting in an 86 base pair PCR product. The methylated template primers were (forward) 
TCGTGGTAACGGAAAAGCGC and (reverse) AAATCTCAACGAACTCACGCCG, resulting in a 75 base 
pair PCR product. These primers have been extensively characterized by previous group[12]. PCR conditions 
were as follows: 95.0°C for 10 minutes, then 35 cycles of 94.0°C for 15 seconds, 55.0°C for 30 seconds, 72.0°C 
for 30 seconds, and a final extension at 72.0°C for 10 minutes. PCR products were electrophoresed on a 2.5% 
agarose gel stained with ethidium bromide and visualized on a UVP Bioimaging system. Specificity of the 
reactions was confirmed using the EpiTect® Control DNA set (Qiagen) with the same primers and PCR 
conditions. The presence of a methylated band was recorded as “positive” for BRCA1 promoter methylation. 
(Figure 1) 
2.3 Data analysis 
Statistical analysis was performed using SPSS 22.0 software. Analysis of patient’s characteristics and BRCA1 
promoter methylation using Pearson chi square and Fischer exact. 
2.4 Ethical Clearance  
Ethical approval for this study was obtained from Research Ethics Committee, Faculty of Medicine, Hasanuddin 
University, Makassar, Indonesia with a number: 390 / H4.8.4.5.31 / PP36/KOMETIK / 2016. 
3. Result 
During the study period from March 2016 until March 2018, we collected breast cancer patient’s data, and 
found 113 sample who met the inclusion-exclusion criteria.  
3.1 Patient Characteristic 
The clinicopathology characteristic summarized in Table 1. In this study the median age at diagnosis was 48 
years old (with range 28-80 years old). Most of them, 67(59,3%) are include in aged categories <50 years. Most 
of histology type are invasive ductal carcinoma 105 (92,9%). Staging was dominated by stage II, 53 (46,9%) 
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were followed by stage III as many as 49 (43,4%). Grading was dominated by grade III, 60 (53,1%) were 
followed by grade II as many as 45 cases (39,8%). From immunohistochemistry staining the majority cases 
showed ER positive 75 (66,4%), PR positive 68 (60,2%), HER2 negative 78 (69%) and Ki 67 positive 
64(56,6%). From molecular subtype we found Luminal B 47(41,6%), Luminal A 31(27,4%), HER 2(17,7%) and 
TNBC (13,3%). In follow-up 40 patient (35,4%) showed metastatic local, regional or distant metastatic. 
Table 1: Patient characteristic 
Characteristic Total (%) 
Age  
<50 
>50 
67 (59,3%) 
46 (40,7%) 
Histology type  
Invasive ductal carcinoma             
Invasive lobular carcinoma    
Mucinous carcinoma          
Papillary carcinoma    
Medullary carcinoma 
105 (92,9%) 
    3(2,7%) 
    2(1,8%) 
    1(0,9%) 
    2(1,8%) 
Stage  
I 
II 
III 
11(9,7%) 
53(46,9%) 
49(43,4%) 
Grade  
I 
II 
III 
8 (7,1%) 
45(39,8%) 
60(53,1%) 
ER  
Negative 
Positive 
38(33,6%) 
75(66,4%) 
PR  
Negative 
Positive 
45(39,8%) 
68(60,2%) 
HER2  
Negative 
Positive 
78(69,0%) 
35(31,0%) 
Ki67  
Negative 
Positive 
49(43,4%) 
64(56,6%) 
Molecular subtype  
Luminal A 
Luminal B 
Her 2 
TNBC 
31(27,4%) 
47(41,6%) 
20(17,7%) 
15(13,3%) 
Metastatis  
Negative 
Positive 
73(64,4%) 
40(35,4%) 
 
C+ C+            Patient1   Patient2  Patient3 Patient4  Patient5   Patient 6 
Mk U   M   NTC   U     M     U    M    U    M    U     M     U    M      U     M 
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Figure 1: BRCA1 promoter methylation. 
DNA methylation status of the BRCA1 promoter determined by MSPCR. U-labeled lanes represent PCR 
products amplified with unmethylated primers (86 bp). M-labeled lanes represent PCR products amplified with 
methylated primers (75 bp). Patients 1, 4, and 6 shows the presence of a PCR product in both reactions, 
indicating BRCA1 methylated (positive).  
Patients 2, 3 dan 5 only shows unmethylated reaction(negative). Mk: Molecular weight marker used is a 100-bp 
ladder. C+U: positive control unmethylated. C+M: positive control methylated. NTC: no template control. 
3.2 Correlation between characteristic patient and BRCA1 promoter methylation 
BRCA1 promoter methylation was detected in 93 (82,3%) of the 113 samples, almost samples were positive for 
both unmethylated and methylated reactions. Only one sample (1,1%) were positive only for the methylated 
reaction.  
The patient in categories aged < 50 years have significant correlation with methylated BRCA1 promoter (p-
value 0,038).  
The significant correlation also showed by Luminal B subtype (p-value 0,033) There is no significant 
correlation between BRCA1 promoter methylation and histology type, staging, grading, ER, PR, HER2, Ki67 
and metastatic.  
3.3 Correlation between subtype molecular and BRCA1 promoter methylation in metastatic patient 
From 113 patient we found metastatic in 40 patient. Most of the metastatic patient showed BRCA1 promoter 
methylation 35(87,5%).  Most of the metastatic patient showed Luminal B subtype 18(45%).  
Despite no correlation significance between molecular subtype and BRCA1 promoter methylation (p-value 
0,330), we found all of HER 2 and TNBC subtype showed Methylated BRCA1 promoter, and none of them 
showed Unmethylated BRCA1 promoter. 
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Table 2:  Correlation between characteristic patient and BRCA1 promoter methylation 
    
Characteristic Total BRCA1 promoter methylation P-Value 
  Unmethylated Methylated  
  N (%) N (%)  
N 113(100%) 20 (17,7%)  93 (82,3%)  
Age at diagnosis     
<50  
>50  
67(59,3%) 
46(40,7%) 
16(80%) 
4(20%) 
51(55%) 
42(45%)  
0,038* 
Morphology     
Invasive ductal carcinoma 
Others 
105(92,9%) 
    8(7,1%) 
20(100%) 
  0 (0%) 
85(91%) 
  8(9%) 
0,199** 
Stage     
I 
II 
III 
11(9,7%) 
53(46,9%) 
49(43,4%) 
  1(5%) 
  9(45%) 
10(50%) 
10(11%) 
44(47%) 
39(42%) 
0,662* 
Grade     
I 
II 
III 
8 (7,1%) 
45(39,8%) 
60(53,1%) 
  0 (0%) 
  9(45%) 
11(55%) 
 8(9%) 
36(39%) 
49(53%) 
0,378* 
ER     
Negative 
Positive 
38(33,6%) 
75(66,4%) 
 5(25%) 
15(75%) 
33(35,5%) 
60(64,5%) 
0,523* 
PR     
Negative 
Positive 
45(39,8%) 
68(60,2%) 
5(25%) 
15(75%) 
40(43%) 
53(57%) 
0,215* 
HER2     
Negative 
Positive 
78(69,0%) 
35(31,0%) 
14(70%) 
  6(30%) 
64(69%) 
29(31%) 
1,000* 
Ki67     
<14 
>14 
49(43,4%) 
64(56,6%) 
5(25%) 
15(75%) 
4(47,3%) 
49(52,7%) 
0,115* 
Molecular subtype     
Luminal A 
Luminal B 
Her 2 
TNBC 
31(27,4%) 
47(41,6%) 
20(17,7%) 
15(13,3%) 
2(10%) 
14(70%) 
3(15%) 
1(5%) 
29(31,2%) 
33(35,5%) 
17(18,3%) 
14(15,0%) 
0,033* 
Metastasis     
Negative 
Positive 
73(64,4%) 
40(35,4%) 
15(75%) 
  5(25%) 
58(62,4%) 
35(37,6%) 
0,210** 
 
Tabel 3: Correlation between subtype molecular and BRCA1 promoter methylation in metastatic patient 
Subtype molecular  BRCA1 promoter methylation p-value 
  Unmethylated Methylated  
Luminal A 9(22,5%) 1(20%) 8 (22,86%) 0,330 
Luminal B 18(45%) 4(80%) 14(40%)  
HER 2 7(17,5%) 0(0%) 7(20%)  
TNBC 6(15%) 0(0%) 6(17,14%)  
 
*Pearson chi square ** Fisher exact test 
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4. Discussion 
Breast cancer is the most cancer in the Indonesian women. Increasing incidence of breast cancer in developing 
country such as Indonesia is caused by improvement socioeconomic that made lifestyle changes including 
dietary changing, obesity, lower physical activity, alcohol, smoking, delayed childbearing, and using hormonal 
contraceptive [19, 20]. BRCA1 promoter hypermethylation has been implicated as one of the mechanisms of 
loss of gene expression and has been identified in 13-59,2% of sporadic breast cancer [6, 7,10–15]. In this study 
we found hypermethylation of BRCA1 is present in 82,3% (92 of 113, that is significantly higher than 
previously report. This result is consistent with Nindrea and his colleagues that found strong correlation between 
BRCA1 promoter hypermethylation and breast cancer in Asia [21]. Some factors may account for these 
differences. First, some research’s report the incidence BRCA1 promoter hypermethylation correlated with 
invasive ductal carcinoma [14, 21] dan grade III [22].  Since most of our samples are invasive ductal carcinoma 
82,3% (93 of 113) and high grade 53,1% (60 of 113), this finding may be comparable to that literature. 
Secondly, although most published studies mentioned above used MSP, the primer sequences, target regions and 
kind of sample (frozen tissue, FFPE block)  varied from study to study [6, 7,10–15].   
From this study we found significant correlation between BRCA1 promoter hypermethylation with patient age 
categories < 50 tahun (55%). The same result also showed in Korean women [23] and African-American 
women[24].  In the other hand BRCA1 promoter hypermethylation correlated with older patient in Caucasian 
women. Globally breast cancer patient < 50 years old usually found in less develop region like Africa (36,2 
years old), Asia (29,1years old),  South East Asia (34,8 years old), and older in American (67,6 years old), 
Europe (71,1 years old) and Australia (85,8 years old)[1] This difference possibly is caused by lifestyle factors, 
diet pattern, or the existence of certain gene which is related to race so that the difference in age occurred..This 
study also observed significant correlation between BRCA1 promoter hypermethylation with Luminal B 
molecular subtype. Our result is different from some studies that found correlation between BRCA1 promoter 
hypermethylation with TNBC[7,10, 14] and Luminal A [25]. Luminal B subtype exhibit low expression of ER 
or PR, variable expression of, and high expression of Ki67. Luminal B correlate with younger age group, high 
grade and nodal metastasis [26]. Despite Luminal B patient can be treat with hormonal therapy and target 
therapy (Anti Her2) beside chemotherapy, they have residual risk [27] and the risk of recurrence and metastasis 
higher than non-luminal [28]. Patients non TNBC who had BRCA1 promoter methylation had significantly 
worse disease-free survival than patients with non-methylated BRCA1 promoters [11]. In this study, most of the 
metastatic patient showed BRCA1 promoter methylation 35(87,5%), and most of them showed Luminal B 
subtype 18(45%) despite not statistically significant. Until now ER, PR, HER2, Ki 67, grade, and lymph node 
involvement used as marker to predict prognosis [29].  Because of BRCA1 promoter methylation can correlate 
with any molecular subtype and poor prognosis we  suggest it as a predictor marker. 
5. Conclusion 
Incidence BRCA1 promoter methylation in Indonesian women breast cancer is higher than the other nations. 
BRCA1 promoter methylation correlate with younger age (< 50 years old) and Luminal B subtype. 
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6. Recommendation 
It is recommend to use BRCA1 promoter methylation as a predictor marker of a poor prognosis especially in 
Luminal B subtype. 
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